Provided by Tiger Trade Technology Pte. Ltd.

Pasithea Therapeutics Corp.

0.5600
+0.00550.99%
Post-market: 0.56810.0081+1.44%19:08 EDT
Volume:483.91K
Turnover:280.61K
Market Cap:18.71M
PE:-0.38
High:0.6044
Open:0.5740
Low:0.5344
Close:0.5545
52wk High:2.06
52wk Low:0.2810
Shares:33.41M
Float Shares:10.20M
Volume Ratio:2.36
T/O Rate:4.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4820
EPS(LYR):-2.9100
ROE:-65.49%
ROA:-36.00%
PB:0.38
PE(LYR):-0.19

Loading ...

Pasithea Therapeutics Receives Nasdaq Extension on Listing Compliance

TIPRANKS
·
Aug 22

Pasithea Therapeutics Wins NASDAQ Extension to Regain $1 Minimum Bid Compliance

Reuters
·
Aug 22

Pasithea Therapeutics Corp Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 15

Pasithea Net Loss Widens 41.9% to $5.27 Million in Q2 2026

Reuters
·
Aug 15

Pasithea Therapeutics Corp Expected to Post a Loss of 16 Cents a Share - Earnings Preview

Reuters
·
Aug 10

Pasithea Therapeutics Announces Annual Shareholder Meeting

Reuters
·
Aug 08

Pasithea Therapeutics Announces Annual Shareholder Meeting

Reuters
·
Jul 30

Pasithea Therapeutics Posts Investor Presentation on Pas-004 MEK Inhibitor Program in NF1 and Solid Tumors

Reuters
·
Jul 21

Pasithea Therapeutics Posts Press Release on Pas-004 Data Presentation at ESMO 2026

Reuters
·
Jul 21

Pasithea Publishes Investor Presentation on Pas-004 Macrocyclic MEK Inhibitor Program in NF1 and Solid Tumors

Reuters
·
Jul 16

Pasithea Therapeutics to Attend B. Riley Securities Mind, Muscle & Vision Summit

Reuters
·
Jul 08

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data

Reuters
·
Jul 06

Pasithea Therapeutics announces updated data from PAS-004 trial

TIPRANKS
·
Jun 30

Pasithea Therapeutics Corp - Protocol Amendment Extends Dose Escalation up to 52mg for Pas-4

THOMSON REUTERS
·
Jun 30

Pasithea Therapeutics Corp - Pas-4 Shows Favorable Safety Profile with Only Grade 1 or 2 Adverse Events

THOMSON REUTERS
·
Jun 30

Pasithea Therapeutics Corp - Initiates Pilot Food Effect Study for Pas-4 Pharmacokinetics

THOMSON REUTERS
·
Jun 30

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-term Safety and Tolerability, and Durable Clinical Activity in Mek/braf-pretreated Patients, Plus Protocol Expansion

THOMSON REUTERS
·
Jun 30

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion

GlobeNewswire
·
Jun 30

Major Investor Quietly Boosts Stake in Pasithea Therapeutics

TIPRANKS
·
Jun 23

Coastlands Capital LP buys 100,000 Pasithea Therapeutics shares for $53,000

Reuters
·
Jun 22